appa10q208.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
[X] Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
For
the quarterly period ended June 30, 2008
OR
[ ]
|
Transition
Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of
1934
|
For
the transition period
from
to
Commission
File Number 001-33221
A.P.
PHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
94-2875566
|
(State
or other jurisdiction
|
(I.R.S.
Employer
|
of
incorporation)
|
Identification
No.)
|
|
|
123
Saginaw Drive
|
|
Redwood
City CA
|
94063
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(650)
366-2626
(Registrant's
telephone number, including area code)
Indicate
by check mark whether the registrant (1) has filed all reports required to
be
filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during
the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements
for
the past 90 days.
Yes
[X] No
[ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting
company. See definition of “large accelerated filer” ,
“accelerated filer” and “smaller reporting company” in Rule 12b-2 of
the Exchange Act. (Check one).
Large
accelerated filer
|
[ ]
|
Accelerated
filer
|
[ ]
|
Non-accelerated
filer
|
[ ]
|
Small
Reporting Company
|
[X]
|
Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act.)
Yes
[ ] No
[X]
At
July
31, 2008, the number of outstanding shares of the Company's common stock, par
value $.01, was 30,891,465.
A.P.
Pharma, Inc
INDEX
Item
1: Financial
Statements:
A.P.
Pharma, Inc.
Condensed
Balance Sheets
(in
thousands)
|
|
June
30, 2008
|
|
|
December
31, 2007
|
|
|
|
(unaudited)
|
|
|
(Note
1)
|
|
Assets
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$ |
20,356 |
|
|
$ |
33,510 |
|
Marketable
securities
|
|
|
1,164 |
|
|
|
1,552 |
|
Accounts
receivable
|
|
|
152 |
|
|
|
152 |
|
Prepaid
expenses and other current assets
|
|
|
489 |
|
|
|
582 |
|
Total
current assets
|
|
|
22,161 |
|
|
|
35,796 |
|
|
|
|
|
|
|
|
|
|
Property
and equipment, net
|
|
|
1,163 |
|
|
|
1,079 |
|
Other
long-term assets
|
|
|
103 |
|
|
|
75 |
|
Total
assets
|
|
$ |
23,427 |
|
|
$ |
36,950 |
|
|
|
|
|
|
|
|
|
|
Liabilities
and Stockholders' Equity
|
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$ |
1,285 |
|
|
$ |
1,437 |
|
Accrued
expenses
|
|
|
3,329 |
|
|
|
4,347 |
|
Accrued
disposition costs
|
|
|
501 |
|
|
|
423 |
|
Total
current liabilities
|
|
|
5,115 |
|
|
|
6,207 |
|
Deferred
revenue
|
|
|
1,000 |
|
|
|
1,000 |
|
Other
long-term liabilities
|
|
|
131 |
|
|
|
269 |
|
Total
liabilities
|
|
|
6,246 |
|
|
|
7,476 |
|
|
|
|
|
|
|
|
|
|
Stockholders'
equity:
|
|
|
|
|
|
|
|
|
Common
stock
|
|
|
138,135 |
|
|
|
137,438 |
|
Accumulated
deficit
|
|
|
(120,900 |
) |
|
|
(107,926 |
) |
Accumulated
other comprehensive loss
|
|
|
(54 |
) |
|
|
(38 |
) |
Total
stockholders' equity
|
|
|
17,181 |
|
|
|
29,474 |
|
Total
liabilities and stockholders' equity
|
|
$ |
23,427 |
|
|
$ |
36,950 |
|
|
|
|
|
|
|
|
|
|
See
accompanying notes to condensed financial statements.
|
|
|
|
|
|
Condensed
Statements of Operations (unaudited)
(in
thousands, except per share amounts)
|
|
Three
Months Ended June 30,
|
|
|
Six
Months Ended June 30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contract
revenue
|
|
$ |
152 |
|
|
$ |
160 |
|
|
$ |
284 |
|
|
$ |
160 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
5,538 |
|
|
|
3,763 |
|
|
|
11,678 |
|
|
|
8,749 |
|
General
and administrative
|
|
|
863 |
|
|
|
872 |
|
|
|
1,943 |
|
|
|
1,991 |
|
Total
operating expenses
|
|
|
6,401 |
|
|
|
4,635 |
|
|
|
13,621 |
|
|
|
10,740 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
|
(6,249 |
) |
|
|
(4,475 |
) |
|
|
(13,337 |
) |
|
|
(10,580 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income, net
|
|
|
155 |
|
|
|
156 |
|
|
|
436 |
|
|
|
304 |
|
Gain
on sale of interest in royalties
|
|
|
— |
|
|
|
2,500 |
|
|
|
— |
|
|
|
2,500 |
|
Other
income, net,
|
|
|
4 |
|
|
|
3 |
|
|
|
7 |
|
|
|
3 |
|
Loss
from continuing operations
|
|
|
(6,090 |
) |
|
|
(1,816 |
) |
|
|
(12,894 |
) |
|
|
(7,773 |
) |
Income
(loss) from discontinued operations
|
|
|
(40 |
) |
|
|
40 |
|
|
|
(80 |
) |
|
|
32 |
|
Loss
before income taxes
|
|
|
(6,130 |
) |
|
|
(1,776 |
) |
|
|
(12,974 |
) |
|
|
(7,741 |
) |
Provision
for income taxes
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(36 |
) |
Net
loss
|
|
$ |
(6,130 |
) |
|
$ |
(1,776 |
) |
|
$ |
(12,974 |
) |
|
$ |
(7,777 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted net loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
from continuing operations
|
|
$ |
(0.20 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.42 |
) |
|
$ |
(0.98 |
) |
Net
loss
|
|
$ |
(0.20 |
) |
|
$ |
(0.19 |
) |
|
$ |
(0.42 |
) |
|
$ |
(0.98 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
used to compute basic and diluted net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
loss
per share
|
|
|
30,800 |
|
|
|
9,591 |
|
|
|
30,786 |
|
|
|
7,961 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See
accompanying notes to condensed financial statements.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed
Statements of Cash Flows (unaudited)
(in
thousands)
|
|
Six
Months Ended June 30,
|
|
|
|
2008
|
|
|
2007
|
|
Cash
flows from operating activities:
|
|
|
|
|
|
|
Net
loss
|
|
$ |
(12,974 |
) |
|
$ |
(7,777 |
) |
Adjustments
to reconcile net loss to net
|
|
|
|
|
|
|
|
|
cash
used in operating activities:
|
|
|
|
|
|
|
|
|
Loss
(gain) from discontinued operations
|
|
|
80 |
|
|
|
(32 |
) |
Depreciation
and amortization
|
|
|
204 |
|
|
|
189 |
|
Stock-based
compensation expense
|
|
|
578 |
|
|
|
276 |
|
Amortization
of discount and accretion of premium
|
|
|
|
|
|
|
|
|
on
marketable securities
|
|
|
— |
|
|
|
334 |
|
Changes
in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(20 |
) |
|
|
(99 |
) |
Prepaid
expenses and other current assets
|
|
|
93 |
|
|
|
(15 |
) |
Other
long-term assets
|
|
|
(28 |
) |
|
|
15 |
|
Accounts
payable
|
|
|
(152 |
) |
|
|
(55 |
) |
Accrued
expenses
|
|
|
(1,067 |
) |
|
|
(515 |
) |
Net
cash used in continuing operating activities
|
|
|
(13,286 |
) |
|
|
(7,679 |
) |
|
|
|
|
|
|
|
|
|
Net
cash provided by (used in) discontinued
operations
|
|
|
19 |
|
|
|
(4 |
) |
Net
cash used in operating activities
|
|
|
(13,267 |
) |
|
|
(7,683 |
) |
Cash
flows from investing activities:
|
|
|
|
|
|
|
|
|
Purchases
of property and equipment
|
|
|
(288 |
) |
|
|
(31 |
) |
Maturities
of marketable securities
|
|
|
372 |
|
|
|
2,825 |
|
Sales
of marketable securities
|
|
|
— |
|
|
|
5,678 |
|
Net
cash provided by investing activities
|
|
|
84 |
|
|
|
8,472 |
|
|
|
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds
from issuance of common stock, net of issuance cost
|
|
|
— |
|
|
|
37,550 |
|
Proceeds
from the exercise of stock options
|
|
|
2 |
|
|
|
— |
|
Proceeds
from issuance of shares under the
|
|
|
|
|
|
|
|
|
Employee
Stock Purchase Plan
|
|
|
27 |
|
|
|
38 |
|
Net
cash provided by financing activities
|
|
|
29 |
|
|
|
37,588 |
|
|
|
|
|
|
|
|
|
|
Net
increase (decrease) in cash and cash equivalents
|
|
|
(13,154 |
) |
|
|
38,377 |
|
Cash
and cash equivalents, beginning of the period
|
|
|
33,510 |
|
|
|
2,333 |
|
Cash
and cash equivalents, end of the period
|
|
$ |
20,356 |
|
|
$ |
40,710 |
|
|
|
|
|
|
|
|
|
|
See
accompanying notes to condensed financial statements.
|
|
|
|
|
|
|
|
|
Notes
to Condensed Financial Statements
June
30, 2008 and 2007 (unaudited)
(1) BUSINESS
AND BASIS OF PRESENTATION
A.P.
Pharma, Inc. (the “Company”, “we”, “our”, or “us”) is a specialty pharmaceutical
company focused on developing pharmaceutical products using our proprietary
Biochronomer polymer-based drug delivery technology. Our product development
philosophy is based on incorporating approved therapeutics into our proprietary
bioerodible drug delivery technology to create controlled release
pharmaceuticals to improve treatments for diseases or conditions. Our lead
product candidate, APF530, is currently in a pivotal Phase III clinical trial
for the prevention of acute and delayed onset chemotherapy-induced nausea and
vomiting, or CINV. We completed enrollment of our pivotal Phase III clinical
trial in the second quarter of 2008 and to expect to announce results of that
trial in the third quarter of 2008. We expect to submit our new drug
application, or NDA, for approval of APF530 in the fourth quarter of
2008.
Our
primary focus is to advance our proprietary Biochronomer technology, consisting
of bioerodible polymers designed to release drugs over a defined period. The
Biochronomer technology can effectively deliver drugs over periods varying
from
days to several months. We have completed comprehensive animal and
human toxicology studies that have established that our Biochronomer polymers
are safe and well tolerated. We have completed over 100 in vivo and in
vitro studies
demonstrating that our Biochronomer technology is potentially applicable to
a
range of therapeutic areas, including prevention of nausea and vomiting, pain
management, control of inflammation and treatment of ophthalmic diseases. Our
lead product candidate, which utilizes our proprietary Biochronomer technology,
is APF530. APF530 is designed to prevent CINV for at least five days and
contains granisetron, a drug approved for this indication. In September 2005,
we
completed a Phase II clinical trial of APF530 that achieved all of its primary
and secondary endpoints. In May 2006, we initiated our pivotal Phase III
clinical trial with AFP530. We believe that this clinical trial will lead to
regulatory approval of APF530 for the prevention of acute and delayed onset
CINV
for patients undergoing both moderately and highly emetogenic, or
vomit-inducing, chemotherapy.
In
addition to our lead drug candidate, we have a pipeline of other product
candidates. One of these, APF112, incorporates the well-known local anesthetic,
mepivacaine. It is designed to provide up to 36 hours of post-surgical pain
relief and to minimize the use of morphine-like drugs, or opiates, which are
used extensively in post-surgical pain management. Post-surgical pain can be
treated with local anesthetics, but the usefulness of these drugs is currently
limited by the short duration of their effectiveness. A longer acting
local anesthetic would be expected to result in better pain management and
a
reduced need for opiates. Our plan was to initiate a Phase IIb
clinical trial for APF112 in the first half of 2008. However, in late
April 2008, we determined that some recently manufactured batches of our
polymer, AP135, intended for use in our APF112 trial, contained trace amounts
of
an extraneous material not present in previous lots of
APF135. Investigation indicated that this extraneous substance was
introduced into the production process at our contract manufacturer via the
use
of a solvent. Based upon the results of additional testing we believe
that the presence of the material affects only the cosmetic properties of the
polymer and there are no related toxicology or drug release
issues. We are working closely with our manufacturer to establish
permanent and rigorous inspection procedures to prevent the occurrence of any
future contamination.
Corrective
actions have been taken and production of APF112 trial materials was resumed
late in the second quarter of 2008. This has, however, resulted in a
delay in the planned initiation of the APF112 Phase IIb trial into the fourth
quarter of 2008. This manufacturing issue will have no impact on the
APF530 development timelines.
We
have
several additional product candidates using our Biochronomer technology in
early
stages of development. This includes APF580, which incorporates an
opiate into our Biochronomer technology, and is designed to provide analgesia
lasting up to seven days by a single injection. It is targeted for
situations where the intensity and duration of pain require use of an opiate
rather than a local anesthetic.
Animal
studies with APF580 are currently being conducted, and data from those studies
are being supplemented with additional preclinical data from an ongoing research
and development agreement with a major animal health company, which is
evaluating APF580 for use in cats and dogs. We are currently
completing our preparation of the Investigational New Drug Application (IND)
for
APF580.
The
submission of the IND,
which was originally planned for late in the second quarter of 2008, is now
expected in the third quarter of 2008. The delay versus previous expectations
was largely due to an extended period of time for the collection of
certain preclinical information and not a result of the above-mentioned
manufacturing issue involving AP135.
The
accompanying unaudited condensed financial statements have been prepared in
accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for
interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation S-X. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial
statements. All adjustments (all of which are of a normal recurring
nature) considered necessary for a fair presentation have been
included. Operating results for the three and six months ended June
30, 2008 are not indicative of the results that may be expected for the year
ending December 31, 2008 or for any other period. The condensed
balance sheet as of December 31, 2007 has been derived from the audited
financial statements as of that date but it does not include all of the
information and notes required by U.S. GAAP. These condensed
financial statements and the notes thereto should be read in conjunction with
the audited financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2007 filed with the Securities
and
Exchange Commission (the “SEC”) on March 30, 2008 (our “2007
10-K”).
Critical
Accounting Policies and Estimates
The
preparation of financial statements in conformity with U.S. generally accepted
accounting principles requires our management to make estimates and assumptions
about future events that affect the amounts reported in the financial statements
and accompanying notes. Actual results could differ significantly from those
estimates. We believe the following policies to be critical to understanding
our
financial condition, results of operations, and expectations for 2008, because
these policies require management to make significant estimates, assumptions
and
judgments about matters that are inherently uncertain.
• Revenue
Recognition
Our
revenue arrangements with multiple deliverables are divided into separate units
of accounting if certain criteria are met, including whether the delivered
item
has stand-alone value to the customer and whether there is objective and
reliable evidence of the fair value of the undelivered items. The consideration
we receive is allocated among the separate units based on their respective
fair
values, and the applicable revenue recognition criteria are considered
separately for each of the separate units. Advance payments received in excess
of amounts earned are classified as deferred revenue until earned.
• Sale
of Royalty Revenue
In
January 2006, we completed the sale of our rights to royalties on sales of
Retin-A Micro® and Carac® for up to $30 million. We received proceeds
of $25 million upon the closing of the transaction and received a $2.5 million
milestone payment in June 2007. We may receive an additional $2.5
million based on the satisfaction of certain other predetermined
milestones.
• Cash
Equivalents and Short-term Investments
We
invest
excess cash in a variety of high grade primarily short–term interest-bearing
securities. We consider all short-term investments in debt securities
which have original maturities of less than three months at the date of purchase
to be cash equivalents. Investments with maturities of three months
or longer are classified as marketable securities in the accompanying condensed
balance sheets. Marketable securities are classified as available for
sale at the time of purchase and carried at fair value. Unrealized
gains or losses, if any, are recorded as other comprehensive income or loss
in
stockholders’ equity. If the estimated fair value of a security is
below its carrying value, we evaluate whether we have the intent and ability
to
retain our investment for a period of time sufficient to allow for any
anticipated recovery in market value and whether evidence indicating that the
cost of the investment is recoverable within a reasonable period of time
outweighs evidence to the contrary. If the impairment is
considered to be other-than–temporary, the security is written down to its
estimated fair value. Other-than-temporary declines in estimated fair
value of all marketable securities are charged to “other income (loss),
net”. The cost of all securities sold is based on the specific
identification method.
• Contract
Revenue
Contract
revenue relates to research and development arrangements that generally provide
for us to invoice research and development fees based on full-time equivalent
hours for each project. Revenue from these arrangements are recognized as the
related development services are rendered. This revenue approximates the costs
incurred.
• Clinical
Trial
Accruals
Our
expenses related to clinical trials are based on estimates of the services
received and efforts expended pursuant to contracts with multiple research
institutions and clinical research organizations that conduct and manage
clinical trials on our behalf. Since the invoicing related to these services
does not always coincide with our financial statement close process, we must
estimate the level of services performed and fees incurred in determining the
accrued clinical trial costs. The financial terms of these agreements are
subject to negotiation and variation from contract to contract and may result
in
uneven payment flows. Payments under the contracts depend on factors such as
the
successful enrollment of patients or achievement of certain events or the
completion of portions of the clinical trial or similar conditions. The Phase
III clinical trial of APF530 has a significant effect on the Company’s research
and development expenses. Expenses related to clinical trials generally are
accrued based on the level of patient enrollment and services performed by
the
clinical research organization or related service provider according to the
protocol. We monitor patient enrollment levels and related activity to the
extent possible and adjust our estimates accordingly. Historically these
estimates have been accurate and no material adjustments have had to be
made.
• Income
Taxes
We
make
certain estimates and judgments in determining income tax expense for financial
statement purposes. These estimates and judgments occur in the calculation
of
certain tax assets and liabilities, which arise from differences in the timing
of recognition of revenue and expense for tax and financial statement purposes.
As part of the process of preparing our financial statements, we are required
to
estimate our income taxes in each of the jurisdictions in which we operate.
This
process involves us estimating our current tax exposure under the most recent
tax laws and assessing temporary differences resulting from differing treatment
of items for tax and accounting purposes.
We
assess
the likelihood that we will be able to recover our deferred tax assets. We
consider all available evidence, both positive and negative, including our
historical levels of income and losses, expectations and risks associated with
estimates of future taxable income and ongoing prudent and feasible tax planning
strategies in assessing the need for a valuation allowance. If we do not
consider it more likely than not that we will recover our deferred tax assets,
we will record a valuation allowance against the deferred tax assets that we
estimate will not ultimately be recoverable. At June 30, 2008, we believed
that
the amount of our deferred income taxes would not be ultimately recovered.
Accordingly, we recorded a full valuation allowance for deferred tax assets.
However, should there be a change in our ability to recover our deferred tax
assets, we would recognize a benefit to our tax provision in the period in
which
we determine that it is more likely than not that we will recover our deferred
tax assets.
• Stock-Based
Compensation
We
measure stock-based compensation at the grant date based on the award’s fair
value and recognize the expense ratably over the requisite vesting period,
net
of estimated forfeitures, for all stock-based awards granted after
January 1, 2006 and all stock-based awards granted prior to, but not vested
as
of January 1, 2006.
We
have
elected to calculate an award’s fair value based on the Black-Scholes
option-pricing model. The Black-Scholes model requires various
assumptions, including expected option life and volatility. If any of
the assumptions used in the Black-Scholes model or the estimated forfeiture
rate
changes significantly, stock-based compensation expense may differ materially
in
the future from that recorded in the current period. Prior to January
1, 2008, we calculated the expected term of an option using the simplified
method provided in Staff Accounting Bulletin No. 107 and starting January 1,
2008, we are using historical data to calculate the expected option
term.
Recent
Accounting Pronouncements
Effective
January 1, 2008 we adopted SFAS 157, Fair Value Measurements
(“SFAS157”). In February 2008, the FASB issued FASB Staff Position
No. FAS 157-2,
Effective Date of FASB Statement No 157, which provides a one year
deferral (effective for years beginning after November 15, 2008) of the
effective date of SFAS 157 for non-financial assets and non-financial
liabilities, except those that are recognized or disclosed in the financial
statements at fair value at least annually. Therefore, we have
adopted the provisions of SFAS 157 with respect to our financial assets and
liabilities only. SFAS 157 defines fair value, establishes a
framework for measuring fair value under generally accepted accounting
principles and enhances disclosures about fair value
measurements. Fair value is defined under SFAS 157 as the exchange
price that would be received for an asset or paid to transfer a liability (an
exit price) in the principal or most advantageous market for the asset or
liability in an orderly transaction between market participants on the
measurement date. Valuation techniques used to measure fair value under SFAS
157
must maximize the use of observable inputs and minimize the use of unobservable
inputs. The standard describes a fair value hierarchy based on three
levels of inputs, of which the first two are considered observable and the
last
unobservable, that may be used to measure fair value which are the
following:
·
|
Level
1 – Quoted prices in active markets for identical assets or
liabilities.
|
·
|
Level
2 - Inputs other than Level 1 that are observable, either
directly or indirectly, such as quoted prices for similar
assets or liabilities; quoted prices in markets that are not active;
or
other inputs that are observable or can be corroborated by observable
market data for substantially the full term of the assets or
liabilities.
|
·
|
Level
3 – Unobservable inputs that are supported by little or no market activity
and that are significant to the fair value of the assets or
liabilities.
|
The
adoption of this statement did not have a material impact on our results of
operations, financial condition or cash flow.
Effective
January 1, 2008 we adopted SFAS No. 159, The Fair Value Option for
Financial
Assets and Financial Liabilities- including an amendment of FASB
Statement No. 115 (“SFAS 159”). SFAS 159 allows an entity the
irrevocable option to elect fair value for the initial and subsequent
measurement for specified financial assets and liabilities on a
contract-by-contract basis. We did not elect to apply the fair value option
under SFAS 159.
Effective
January 1, 2008, we adopted EITF 07-3, Accounting for Advance Payments
for
Goods and Services to be Received for Use in Future Research and Development
Activities (“EITF 07-03). EITF 07-03 requires that
non-refundable advance payments for goods or services that will be used or
rendered for future research and development activities be deferred and
capitalized and recognized as an expense as the goods are delivered or the
related services are performed, subject to an assessment of
recoverability. The adoption did not have a material
impact on our results of operations or financial condition.
In
November 2007, the EITF issued EITF Issue No. 07-1 ("EITF 07-1"), Accounting for Collaborative
Arrangements Related to the Development and Commercialization of Intellectual
Property. Companies may enter into arrangements with other companies to
jointly develop, manufacture, distribute, and market a product. Often the
activities associated with these arrangements are conducted by the collaborators
without the creation of a separate legal entity (that is, the arrangement is
operated as a "virtual joint venture"). The arrangements generally
provide that the collaborators will share, based on contractually defined
calculations, the profits or losses from the associated activities.
Periodically, the collaborators share financial information related to product
revenues generated (if any) and costs incurred that may trigger a sharing
payment for the combined profits or losses. The consensus requires collaborators
in such an arrangement to present the result of activities for which they act
as
the principal on a gross basis and report any payments received from (made
to)
other collaborators based on other applicable GAAP or, in the absence of other
applicable GAAP, based on analogy to authoritative accounting literature or
a
reasonable, rational, and consistently applied accounting policy
election. EITF 07-1 is effective for collaborative arrangements in
place at the beginning of the annual period beginning after December 15,
2008. Management does not expect that the adoption EITF 07-1 will
have a material impact on our financial position and results of
operations.
In
December 2007, the FASB issued SFAS 141 (revised 2007), Business Combinations
(“SFAS141R”). SFAS 141R establishes principles and requirements for how an
acquirer recognizes and measures in its financial statements the identifiable
assets acquired, the liabilities assumed, any non-controlling interest of the
acquiree and the goodwill acquired. SFAS 141R also establishes disclosure
requirements to enable the evaluation of the nature and financial effects of
the
business combination. This statement is effective for us beginning
January 1, 2009. We will assess the potential impact of the adoption of
SFAS 141R if and when a future acquisition occurs.
In
December 2007, the FASB approved the issuance of SFAS No. 160. Non-controlling Interests
in
Consolidated Financial Statements – an amendment of ARB No. 51 (“SFAS
160”). SFAS 160 will change the accounting and reporting for minority
interests, which will now be termed non-controlling
interests. SFAS 160 requires non-controlling interest to be
presented as a separate component of equity and requires the amount of net
income attributable to the parent and to the non-controlling interest to be
separately identified on the consolidated statement of
operations. SFAS 160 is effective for fiscal years beginning on or
after December 15, 2008. At this time, we do not expect adoption of
SFAS 160 to have any impact on our financial position, results of operations
or
cash flows.
In
March
2008, the FASB issued FAS No. 161, Disclosures about Derivative
Instruments and Hedging Activities – an amendment of FASB Statement No. 133
( “SFAS 161”). SFAS 161 requires enhanced disclosure related
to derivatives and hedging activities and thereby seeks to improve the
transparency of financial reporting. Under SFAS 161, entities are
required to provide enhanced disclosures relating to: (a) how and why
an entity uses derivative instruments; (b) how derivative instruments and
related hedge items are accounted for under SFAS 133 Accounting for Derivative
Instruments and Hedging Activities (“SFAS 133’) and its related
interpretations; and (c) how derivative instruments and related hedged items
affect an entity’s financial position, financial performance and cash
flows. SFAS 161 must be applied prospectively to all derivative
instruments and non-derivative instruments that are designated and qualify
as
hedging instruments and related hedged items accounted for under SFAS 133 for
all financial statements issued for fiscal years and interim periods beginning
after November 15, 2008. We do not expect adoption of SFAS 161 to have any
impact on our financial position, results of operations or cash
flows.
In
April
2008, the FASB issued FASB Staff Position No. FAS 142-3 Determination of the Useful
Life of
Intangible Assets (“FSP 142-3”). FSP 142-3 amends the factors
that should be considered in developing renewal or extension
assumptions used to determine the useful life of a recognized intangible asset
under FASB Statement No 142 Goodwill and Other Intangible
Assets and requires enhanced disclosures relating to: (a) the entity’s
accounting policy on the treatment costs incurred to renew or extend the term
of
a recognized intangible asset; (b) in the period of acquisition or renewal,
the
weighted-average period prior to the next renewal or extension (both explicit
and implicit), by major intangible asset class and (c) for an entity that
capitalizes renewal or extension costs, the total amount of costs incurred
in
the period to renew or extend the term of a recognized intangible asset for
each
period for which a statement of financial position is presented by major
intangible asset class. FSP 142-3, must be applied prospectively to
all intangible assets acquired as of and subsequent to fiscal years beginning
after December 15, 2008, and interim periods within those fiscal
years. Early adoption is prohibited. We do not expect
adoption of FSP142-3 to have any impact on our financial position, results
of
operations or cash flows.
(2) FAIR
VALUE
In
accordance with SFAS 157, the following table represents the Company’s fair
value hierarchy for its financial assets (cash equivalents and investments)
measured at fair value on a recurring basis as of June 30, 2008 (in
thousands):
|
Level
1
|
|
Level
2
|
|
Level
3
|
|
Total
|
Money
market funds
|
$
|
20,033
|
|
$
|
|
|
$
|
|
|
$
|
20,033
|
Asset
backed securities
|
|
—
|
|
|
1,164
|
|
|
|
|
|
1,164
|
Total
|
$
|
20,033
|
|
$
|
1,164
|
|
$
|
|
|
$
|
21,197
|
(3) NET
LOSS PER SHARE INFORMATION
Basic
and
diluted net loss per share is computed by dividing net loss by the weighted
average number of common shares outstanding. Diluted net loss per share
excludes the effect of potentially dilutive securities because they are
anti-dilutive. Such potentially dilutive securities at June 30, 2008
include outstanding stock options for 1,586,480 common shares and unearned
restricted stock awards for 72,750 common shares.
(4)
STOCK-BASED COMPENSATION
The
following table shows the stock-based compensation expense for all awards (in
thousands except per share amount):
|
|
Three
Months Ended
June
30,
|
|
|
Six
Months Ended
June
30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$ |
220 |
|
|
$ |
48 |
|
|
$ |
285 |
|
|
$ |
104 |
|
General
and administrative
|
|
|
63 |
|
|
|
65 |
|
|
|
293 |
|
|
|
172 |
|
Total
stock-based compensation expense
|
|
$ |
283 |
|
|
$ |
113 |
|
|
$ |
578 |
|
|
|
276 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact
on basic and diluted net loss per common share
|
|
$ |
.01 |
|
|
$ |
.01 |
|
|
$ |
.02 |
|
|
$ |
.03 |
|
The
following table summarizes option activity for the six months ended June 30,
2008:
|
Shares
|
|
Weighted
Average
Exercise
Price
|
Outstanding
at January 1, 2008
|
550,383
|
|
$ 8.57
|
Granted
|
1,099,300
|
|
$ 1.42
|
Expired
and Forfeited
|
(61,495
|
)
|
$ 8.74
|
Exercised
|
(1,708
|
)
|
$ 1.37
|
Outstanding
at June 30, 2008
|
1,586,480
|
|
$ 3.62
|
Employee
Stock Purchase Plan.
We adopted an Employee Stock Purchase Plan (the “Purchase Plan”) in 1997.
Qualified employees may elect to have a certain percentage of their salary
withheld to purchase shares of our common stock under the Purchase Plan. The
purchase price per share is equal to 85% of the fair market value of the stock
on specified dates. Sales under the purchase plan in the six months
periods ending June 30, 2008 and 2007 were 26,103 and 11,254 shares at an
average price of $1.03 and $3.40 per share respectively. Shares
available for future purchase under the Purchase Plan are 107,057 at June 30,
2008.
We
modified our ESPP such that the length of all offering periods, beginning May
1,
2008 is six months. Consequently, there is no reset feature associated with
any
new offering period. Our closing stock price on the April 30, 2008 ESPP purchase
date was lower than the closing price on the November 1, 2007 offering date.
As
a result, participants were re-enrolled into a new six-month offering period,
beginning May 1, 2008 and ending October 31, 2008. As a result of the amendment,
$41 of compensation cost was accelerated or generated of which $33 was
recognized during the quarter ended June 30, 2008.
(5) COMPREHENSIVE
LOSS
Comprehensive
loss for the three and six months ended June 30, 2008 and 2007 consists of
the
following (in thousands):
|
|
Three
Months Ended
June
30,
|
|
|
Six Months
Ended
June
30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Net
loss
|
|
$ |
(6,130 |
) |
|
$ |
(1,776 |
) |
|
$ |
(12,974 |
) |
|
$ |
(7,777 |
) |
Unrealized
gains (losses) on available-for-sale marketable
securities
|
|
|
(4 |
) |
|
|
5 |
|
|
|
(16 |
) |
|
|
12 |
|
Comprehensive
loss
|
|
$ |
(6,134 |
) |
|
$ |
(1,771 |
) |
|
$ |
(12,990 |
) |
|
$ |
(7,765 |
) |
(6) INCOME
TAXES
There
is
no provision for income taxes for the three or six months ended June 30, 2008
because we incurred net operating losses. In the first quarter of
2007 we recorded a catch up provision of $36 for California State Alternative
Minimum Tax.
(7) STOCKHOLDERS’
EQUITY
In
June,
2007, we sold 24,393,939 shares of common stock in a public offering at a price
of $1.65 per share, for net proceeds of approximately $37.2 million after
deducting underwriting fees and costs associated with the offering. The shares
were offered under our registration statement on Form S-1, as amended
(Registration No. 333-141918).
On
May 23, 2007, we filed a Certificate of Amendment to our Certificate of
Incorporation with the Secretary of State of the State of Delaware affecting
a
1-for-4 reverse stock split of our common stock. All share and per share amounts
for all periods presented have been retroactively restated to reflect the
reverse stock split.
(8) DISCONTINUED
OPERATIONS
We
completed the sale of certain assets of our Analytical Standards division as
well as certain technology rights for our topical pharmaceutical and
cosmeceutical product lines and other assets ("cosmeceutical and toiletry
business") in February 2003 and July 2000, respectively.
The
Analytical Standards division and cosmeceutical and toiletry business are
reported as discontinued operations for all periods presented in the
accompanying Condensed Statements of Operations.
Income
(loss) from discontinued operations represents primarily the loss attributable
to changes in estimates of our cosmeceutical and toiletry business that was
sold
to RP Scherer on July 25, 2000, as follows (in thousands):
|
|
Three
Months Ended
June
30,
|
|
|
Six
Months Ended
June
30,
|
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
Analytical
Standards
Division
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties
earned in excess of minimum
amount recorded
|
|
$ |
—
|
|
|
$ |
1 |
|
|
$ |
—
|
|
|
$ |
17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cosmeceutical
and Toiletry
Business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
in estimates for gross profit guarantees
|
|
|
(40 |
) |
|
|
39 |
|
|
|
(80 |
) |
|
|
15 |
|
Total
income (loss) from discontinued operations
|
|
$ |
(40 |
) |
|
$ |
40 |
|
|
$ |
(80 |
) |
|
$ |
32 |
|
Basic
and
diluted income (loss) per common share from discontinued operations was less
than $0.01 per share for the three and six months ended June 30, 2008 and
2007.
As
of
June 30, 2008, liabilities related to the discontinued operations in the amount
of $501 represent accruals for gross profit guarantees. These liabilities are
reported as accrued disposition costs in the accompanying balance
sheets.
The
cash
provided by discontinued operations of $19 in 2008 relates to royalties received
from GFS Chemicals, Inc. (“GFS”), a privately held company based in Columbus,
Ohio, from sales of Analytical Standards products. The cash used in discontinued
operations of $4 in 2007 relates to a payment of $52 in conjunction
with the Gross Profit Guaranty offset by royalties received
from GFS from sales of Analytical Standards products.
On
February 13, 2003, we completed the sale of our Analytical Standards
division to GFS. In this transaction, we received $2.1 million on closing and
were entitled to receive royalties on sales of Analytical Standards products
for
a period of five years following the sale at rates ranging from 5% to
15%. As of June 30, 2008, all royalties due from GFS have been
received.
In
conjunction with the terms of an agreement with RP Scherer, a subsidiary of
Cardinal Health, where we sold certain technology rights associated with our
cosmeceutical and toiletry business, we guaranteed a minimum gross profit
percentage on RP Scherer’s combined sales of products to Ortho Neutrogena and
Dermik (“Gross Profit Guaranty”). The guaranty period commenced on July 1,
2000 and ends on the earlier of July 1, 2010 or the end of two consecutive
guaranty periods where the combined gross profit on sales to Ortho and Dermik
equals or exceeds the guaranteed gross profit (the “two period test”). The Gross
Profit Guaranty expense totaled $944 for the first seven guaranty years and
in
those years profits did not meet the two period test. Effective March 2007,
in
conjunction with a sale of assets by RP Scherer’s successor company to an Amcol
International subsidiary (“Amcol”), a new agreement was signed between us and
Amcol to provide continuity of product supply to Ortho and Dermik. This new
agreement potentially extends the gross profit guaranty period an additional
three years to July 1, 2013 unless it is terminated earlier with the two period
test. Therefore, we expect the annual Gross Profit Guaranty payment to range
from $100 to $200 per annum. Amcol has indicated that its costs differ from
those it charged historically to the RP Scherer successor company to produce
the
product; we have requested documentation of actual costs and have accrued for
2008 at the historical rate. As there is no minimum amount of Gross Profit
Guaranty due, no accrual for the guaranty is estimable for future years. A
liability of $501 and $420 related to the amount due under the gross profit
guaranty is included in accrued disposition costs as of June 30, 2008 and
December 31, 2007, respectively.
(9)
SUBSEQUENT EVENTS
On
July
3, 2008, our Board of Directors approved an increase to the number of shares
available for grant under our Non-Qualified Stock Option Plan by one million
shares. The Non-Qualified Stock Option Plan is used for inducement
grants.
On
July
7, 2008 we announced the appointment of Ronald Prentki as our President and
Chief Executive Officer (CEO). In conjunction with Ron’s appointment, he was
granted a stock option for 1.4 million shares. The options vest over a four
year
period with 25% of the shares vesting one year from July 7, 2008 and have an
exercise price of $1.19, the fair market value on the date of the
grant.
Forward-looking
Statements
This
Form
10-Q contains "forward-looking statements" as defined by the Private Securities
Reform Act of 1995. These forward-looking statements involve risks and
uncertainties including uncertainties associated with timely development,
approval, launch and acceptance of new products, satisfactory completion of
clinical studies, establishment of new corporate alliances, progress in research
and development programs, reliance on third parties, including contract
manufacturers and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. We caution investors
that forward-looking statements reflect our analysis only on their stated
date. We do not intend to update them except as required by
law.
Results
of Operations for the Three and Six Months Ended June 30, 2008 and 2007 (in
thousands unless otherwise indicated)
Contract
revenue, which is derived from work performed under collaborative research
and
development arrangements, was $152, $160, $284 and $160 for the three months
ended June 30, 2008 and 2007 and the six months ended June 30, 2008 and 2007,
respectively. The amount of contract revenue varies from period to
period depending on the level of activity requested of us by our
collaborators. Therefore, we cannot predict the amount of contract
revenue in future periods.
Research
and development expense for the three months ended June 30, 2008 increased
by
$1,775 from $3,763 for the three months ended June 30, 2007 to $5,538. The
increase was primarily as a result of an increase in our APF530 Phase 3 clinical
trial and related costs. Additionally, there were increases in costs
associated with our post-operative pain product and our undisclosed opiate
pain
product. Salaries and related costs, including stock based
compensation, increased to support the increased activities and outside costs
also increased. Research and development expense for the six months
ended June 30, 2008 increased by $2,929 from $8,749 for the six months ended
June 30, 2007 to $11,678. The increase was primarily due to increased
expenses for our undisclosed opiate pain product, increased clinical trial
and
related expenses for APF530 and increased expenses for our post-operative pain
product. Salaries and related costs, including stock based
compensation, also increased to support the increased clinical
activities, as did outside costs. We expect research and
development expense to decrease in the second half of 2008, reflecting the
completion of our Phase 3 study for APF530.
General
and administrative expense decreased for the three months ended June 30, 2008
by
$9 from $872 for the three months ended June 30, 2007, to
$863. General and administrative expense decreased by $48 for the six
months ended June 30, 2008 from $1991 for the six months ended June 30, 2007,
to
$1943. Stock-based compensation expense was higher for the six months
offset by lower outside services and salaries. We expect general and
administrative expense in the second half of 2008 to increase due to the
appointment of our new Chief Executive Officer and costs associated with other
executive recruitment activities.
Interest
income, net, increased for the six months ended June 30, 2008 by $132 to $436
from $304 for the six months ended June 30, 2007 primarily due to higher average
balance of cash, cash equivalents and marketable securities.
In
January 2006, we completed the sale of our rights to royalties on sales of
Retin-A Micro® and Carac® for up to $30 million. We received proceeds of $25
million upon the closing of the transaction and received a $2.5 million
milestone payment in June 2007, which was recorded as gain on sale of interest
in royalties. We may receive up to an additional $2.5 million based on the
satisfaction of certain other predetermined milestones.
Loss
from
discontinued operations represents the net income/loss attributable to the
Analytical Standards division which was sold to GFS Chemicals, Inc. in February
2003 and the cosmeceutical and toiletries business which was sold to RP Scherer
Corporation in July 2000. Net loss from discontinued operations
totaled $40 for the three months ended June 30, 2008, compared to net income
of
$40 in the three months ended June 30, 2007. Net loss from
discontinued operations totaled $80 for the six months June 30, 2008 compared
to
net income of $32 for the six months ended June 30, 2007. The loss for the
three
and six months ended June 30, 2008 reflects our expectation that the Gross
Profit Guaranty payment for 2008 will be in the range of $100 to $200 for
2008. The company that now owns rights to the cosmeceutical and
toiletries business has indicated that its costs differ from those it charged
historically to the RP Scherer successor company to produce the product; we
have
requested documentation of actual costs.
Capital
Resources and Liquidity
Cash
and
cash equivalents decreased by $13.1 million to $20.4 million at June 30, 2008
from $ 33.5 million at December 31, 2007 due primarily to our net loss for
the
six months ended June 30, 2008.
Net
cash
used in continuing operating activities for the six months ended June 30, 2008
was $13.3 million, compared to net cash used of $7.7 million for the six months
ended June 30, 2007. The increase in net cash used by continuing operating
activities from 2008 to 2007 was mainly due to the increased loss in 2008,
as
compared to the same period in 2007.
Net
cash
provided by investing activities for the six months ended June 30, 2008 was
$84,
compared to net cash provided of $8.5 million from investing activities for
the
six months ended June 30, 2007. The decrease in cash provided by investing
activities was primarily due to lower sales and maturities of marketable
securities in the six months ended June 30, 2008, as compared to the same period
in 2007.
In
the
six months ended June 30, 2007 $37.6 million cash was provided by proceeds
from
issuance of common stock, net of estimated issuance costs.
To
date,
we have financed our operations including technology and product research and
development through the sale of common stock, royalties received on sales of
Retin-A Micro® and Carac®, income from collaborative research and development
fees, the proceeds received from the sales of our Analytical Standards division
and our cosmeceutical and toiletry business, interest earned on short-term
investments and the sale of our interest in the royalty income from Retin-A
Micro® and Carac®. We believe our existing cash, cash equivalents and marketable
securities, together with interest income will be sufficient to meet our cash
needs for at least one year. We anticipate expenditures to decrease as
activities associated with our Phase III APF530 trial are winding
down.
Our capital
requirements going forward from 2008 will depend on numerous factors including,
among others, our ability to enter into collaborative research and development
and licensing agreements; progress of product candidates in preclinical and
clinical trials; investment in new research and development programs; time
required to gain regulatory approvals; resources that we devote to self-funded
products; resources required for gross margin guarantees, potential acquisitions
of technology, product candidates or businesses; and the costs of defending
or
prosecuting any patent opposition or litigation necessary to protect our
proprietary technology.
We
may
not be able to raise sufficient additional capital when we need it or to raise
capital on favorable terms. The sale of additional equity or
convertible debt securities in the future may be dilutive to our stockholders,
and debt financing arrangements may require us to pledge certain assets and
enter into covenants that could restrict certain business activities or our
ability to incur further indebtedness and may contain other terms that are
not
favorable to us or our stockholders. If we are unable to obtain
adequate funds on reasonable terms, we may be required to curtail operations
significantly or to obtain funds by entering into financing, supply or
collaboration agreements on unattractive terms.
Below
is
a summary of fixed payments related to certain contractual obligations (in
thousands). This table excludes amounts already recorded on our
condensed balance sheet as current liabilities at June 30, 2008.
|
|
Total
|
|
|
Less
than
1
year
|
|
|
2
to 3
years
|
|
|
4
to 5
Years
|
|
|
More
than
5
years
|
|
Other
Operating Leases
|
|
$ |
1,534 |
|
|
$ |
544 |
|
|
$ |
956 |
|
|
$ |
34 |
|
|
$ |
—
|
|
Our
exposure to interest rate risk relates primarily to our investment portfolio.
We
do not use derivative financial instruments. We manage our interest
rate risk by maintaining an investment portfolio primarily consisting of debt
instruments of high credit quality and relatively short average
maturities. At June 30, 2008, 93% of our cash, cash equivalents and
marketable securities was held in money market funds.
Evaluation
of disclosure controls and procedures: We carried out an evaluation,
under the supervision and with the participation of our management, including
the Chief Executive Officer and the Interim Chief Financial Officer, of the
effectiveness of the design and operations of our disclosure controls and
procedures pursuant to Rule 13a-15(e) and 15(d)-15(e) of the Exchange
Act. Based upon that evaluation, the Chief Executive Officer and
Interim Chief Financial Officer concluded that as of June 30, 2008, the end
of
period covered by this report, our disclosure controls and procedures were
effective at the reasonable assurance level to alert them in a timely manner
to
material information relating to the Company required to be included in our
Exchange Act filings.
Changes
in internal controls: During the three and six months ended
June 30, 2008, there have been no changes in our internal control
over financial reporting that materially affected, or are reasonably likely
to
materially affect, our internal control over financial reporting.
There
have been no material changes to the risk factors set forth in the "RISK
FACTORS" section of our Annual Report on Form 10-K for the fiscal year ended
December 31, 2007.
Our
annual shareholders’ meeting was held on May 28, 2008, at which the following
proposals were approved.
Proposal
I:
Election of the following directors:
|
Votes
For
|
|
Votes
Withheld
|
Paul
Goddard
|
21,560,039
|
|
3,093,472
|
Peter
Riepenhausen
|
21,580,967
|
|
3,072,544
|
Toby
Rosenblatt
|
21,451,544
|
|
3,201,967
|
Arthur
Taylor
|
21,579,015
|
|
3,074,496
|
Gregory
Turnbull
|
21,565,165
|
|
3,088,346
|
Robert
Zerbe
|
21,579,539
|
|
3,073,972
|
Proposal
II:
To ratify the appointment of Odenberg, Ullakko, Muranishi & Co. LLP as the
Company’s independent registered public accounting firm for the year ending
December 31, 2008.
Votes
For
|
|
Votes
Against
|
|
Abstain
|
24,524,835
|
|
104,681
|
|
23,995
|
On
July
3, 2008, our Board of Directors approved an increase to the number of shares
available for grant under our Non-Qualified Stock Option Plan by one million
shares. The Non-Qualified Stock Option Plan is used for inducement
grants.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
A.P.
PHARMA, INC.
|
|
|
|
|
|
|
Date:
August 14, 2008
|
|
/s/
Ronald J. Prentki
|
|
|
Ronald
J. Prentki
|
|
|
President
and Chief Executive Officer
|
|
|
|
Date:
August 14, 2008
|
|
/s/
Gregory Turnbull
|
|
|
Gregory
Turnbull
|
|
|
Interim
Chief Financial Officer
|
appa10q208ex311.htm
Exhibit
31.1
SECTION
302 CERTIFICATIONS
I,
Ronald
J. Prentki, certify that:
1.
|
I
have reviewed this quarterly report on Form 10-Q of A.P. Pharma,
Inc.
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such
statements
were made, not misleading with respect to the period covered by
this
report;
|
3.
|
Based
on my knowledge, the financial statements, and other financial
information
included in this report, fairly present in all material respects
the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
4.
|
The
registrant’s other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures
and
internal control over financial reporting (as defined in Exchange
Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
|
a)
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant is
made known
to us by others, particularly during the period in which this report
is
being prepared;
|
b)
|
Designed
such internal control over financial reporting, or caused such
internal
control over financial reporting to be designed under our supervision
to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
c)
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the
period
covered by this report based on such evaluation;
and
|
d)
|
Disclosed
in this report any change in the registrant's internal control
over
financial reporting that occurred during the registrant's most
recent
fiscal quarter that has materially affected, or is reasonably likely
to
materially affect, the registrant's internal control over financial
reporting; and
|
5. The
registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to
the registrant's auditors and the audit committee of registrant's board of
directors:
a)
|
All
significant deficiencies and material weaknesses in the design
or
operation of internal control over financial reporting which could
be
reasonably likely to adversely affect the registrant's ability
to record,
process, summarize and report financial information;
and
|
b)
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control
over financial reporting.
|
Date:
August 14, 2008
/s/
Ronald J.
Prentki
Ronald
J.
Prentki
President
and Chief Executive Officer
appa10q208ex312.htm
Exhibit
31.2
SECTION
302 CERTIFICATIONS
I,
Gregory H. Turnbull, certify that:
1.
|
I
have reviewed this quarterly report on Form 10-Q of A.P. Pharma,
Inc.
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such
statements
were made, not misleading with respect to the period covered by
this
report;
|
3.
|
Based
on my knowledge, the financial statements, and other financial
information
included in this report, fairly present in all material respects
the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this
report;
|
4.
|
The
registrant’s other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures
and
internal control over financial reporting (as defined in Exchange
Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
|
a)
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure
that material information relating to the registrant is made known
to us
by others, particularly during the period in which this report
is being
prepared;
|
b)
|
Designed
such internal control over financial reporting, or caused such
internal
control over financial reporting to be designed under our supervision
to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting
principles;
|
c)
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the
period
covered by this report based on such evaluation;
and
|
d)
|
Disclosed
in this report any change in the registrant's internal control
over
financial reporting that occurred during the registrant's most
recent
fiscal quarter that has materially affected, or is reasonably likely
to
materially affect, the registrant's internal control over financial
reporting; and
|
5. The
registrant's other certifying officer and I have disclosed, based on our
most
recent evaluation of internal control over financial reporting, to
the registrant's auditors and the audit committee of registrant's board of
directors:
a)
|
All
significant deficiencies and material weaknesses in the design
or
operation of internal control over financial reporting which could
be
reasonably likely to adversely affect the registrant's ability
to record,
process, summarize and report financial information;
and
|
b)
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control
over financial reporting.
|
Date:
August 14, 2008
/s/
Gregory H.
Turnbull
Gregory
H. Turnbull
Interim
Chief Financial Officer
appa10q208ex32.htm
Exhibit
32
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of A.P. Pharma, Inc. (the "Company") on
Form 10-Q for the period ending June 30, 2008 as filed with the Securities
and
Exchange Commission on the date hereof (the "Report"), I, Ronald J. Prentki,
President and Chief Executive Officer of the Company, certify, pursuant to
18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:
(1)
|
The
Report fully complies with the requirements of section 13(a) or 15(d)
of
the Securities Exchange Act of 1934;
and
|
(2)
|
The
information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.
|
August
14,
2008
/s/
Ronald J. Prentki
Ronald
J.
Prentki,
President
and Chief Executive Officer
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report of A.P. Pharma, Inc. (the "Company") on
Form 10-Q for the period ending June 30, 2008 as filed with the Securities
and
Exchange Commission on the date hereof (the "Report"), I, Gregory H. Turnbull,
Interim Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:
(1)
|
The
Report fully complies with the requirements of section 13(a) or 15(d)
of
the Securities Exchange Act of 1934;
and
|
(2)
|
The
information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.
|
August 14,
2008
/s/
Gregory H.
Turnbull
Gregory
H. Turnbull,
Interim
Chief Financial Officer
appa10q208ex10-u.htm
July
2, 2008
Mr.
Ronald J.
Prentki
Dear
Ron:
A.
P.
Pharma, Inc. (the “Company”) is pleased to offer you the position of President
and Chief Executive Officer of the Company. The terms of your
employment with the Company are as set forth below:
1. Position.
a. Title. You
will become the President and
Chief Executive Officer
of the Company, working out of the Company’s
headquarters office in Redwood City, California. As such, you will
report to the Company’s Board of Directors (the “Board”). Upon
commencement of employment, you will also be appointed to serve as a member
of
the Board, and as long as you are a Company employee you agree to serve in
such
capacity without additional compensation.
b. Duties. As
President and Chief
Executive Officer, you will have the duties, responsibilities and authority
customarily associated with such position as the Company’s most senior executive
officer, including responsibility for the overall management of the
Company. You agree to the best of your ability and experience that
you will loyally and conscientiously perform all of your duties and obligations
to the Company. During your employment, you further agree that
you: (i) will devote substantially all of your business time and
attention to the business of the Company; (ii) will not render commercial or
professional services of any nature to any other person or organization, whether
or not for compensation, without the prior written consent of the Board which
will not be unreasonably withheld; and (iii) will not directly or indirectly
engage or participate in any business or activity that is competitive in any
manner with the business of the Company. Nothing in this letter
agreement will prevent you from serving on advisory boards or boards of
charitable organizations, so long as such service does not unduly interfere
with
the performance of your duties to the Company. The Company also
requests that you not accept nor seriously discuss joining the board of any
public or private for-profit company without first seeking the permission of
the
Nominating and Governance Committee of the Company. While you are an
executive officer and director of the Company, the Company will assist you
in
satisfying your reporting obligations under Section 16 of the Securities
Exchange Act of 1934 (the “Exchange Act”).
Mr. Ronald J. Prentki
July 2, 2008
Page 2
2. Start
Date. Subject to fulfillment of any pre-conditions imposed by
this letter agreement, you will commence full-time employment with the Company
on a mutually agreed upon start
date (the “Start Date”).
3. Compensation
and Benefits.
a. Base
Salary. For all services rendered to the Company, you will
receive a bi-weekly base salary of not less than $16,346.15
(which on an annualized
basis equals $425,000), which will be paid in accordance with the Company’s
regular bi-weekly payroll practice. For purposes of this letter agreement,
the
term “Base Salary” means the annual base salary set forth in this Section 3.a.
or, to the extent the amount of such Base Salary is adjusted upward from time
to
time in the future pursuant to the Company’s annual review process, your
annualized base salary as applicable on the relevant date. The
Board’s Compensation and Stock Option Committee (the “Committee”) will
periodically review your Base Salary followed by a recommendation to the board
for possible increase, the first
such review will take place
in not more than 12 months from the Start Date.
b. Incentive
Bonuses. Except as set forth below with respect to the period
ending on December 31, 2008, you will be eligible to earn an annual incentive
bonus with an annual target amount equivalent to 50% of your Base Salary
(“Target Bonus”). Your right to be paid an annual incentive bonus
under this Section 3.b. will be based on your continued employment throughout
each applicable performance period (subject to Section 7) and the satisfaction
of operating performance metrics and other milestones established by the
Committee in its sole discretion (but with input from you) with respect to
such
period, all subject to final approval by the board. Such performance
metrics and milestones will be established no later than 60 days after the
start
of the applicable performance period; provided that with respect
to
2008, such metrics and milestones will be established on or before September
30,
2008. The actual amount of bonus paid, assuming certification by the
Committee and subsequently the board that the objectives have been achieved
and
the level of such achievement, may be more or less than the Target Bonus
amount. Any bonus payable under this Section 3.b. will be payable
within 60 days following the end of the applicable performance period (provided that you remain employed
on the last day of the applicable performance period). With respect
to 2008, any bonus amount earned and that becomes payable will be pro-rated
from
your Start Date through December 31, 2008.
c. Benefits. The
Company will provide you with the opportunity to participate in benefits plans
and programs of the Company, if any, to the extent your position, tenure and
other qualifications make you eligible to participate, subject to any
eligibility requirements imposed by such plans. You will be entitled to reasonable
vacation time each year based on your reasonable judgment as to an appropriate
and beneficial amount of vacation time relative to the responsibilities of
your
position. You
will be expected to use all vacation time in the year earned. You
will not accrue any days of vacation time based upon your days of
service. You will also be entitled to paid time off for holidays based on the
Company’s written policies as then in effect. The Company reserves
the right to cancel or change the benefit plans and programs it offers to its
employees at any time.
Mr. Ronald J.
Prentki
July 2,
2008
Page
3
d. Indemnification. Commencing
as of the Start Date, you will be covered under the Company’s insurance policies
(the “Policies”) for directors’ and officers’ liability coverage and will be
provided indemnification to the maximum extent permitted by the Company’s Bylaws
and Certificate of Incorporation, including becoming a party to the Company’s
standard indemnification agreement (the “Indemnification
Agreement”). Such coverage and indemnification will be on terms no
less favorable than provided to any other Company senior executive or
director. The indemnification and liability insurance shall cover
events occurring at any time during the period in which you are rendering
services in any capacity to the Company, even if such claims are brought
after
the end of such service period in accordance with the terms of the Policies
and
the Indemnification Agreement. In the event of any claims covered by
them, you will be entitled to have your costs paid and fees advanced by the
Company in accordance with the terms of the Policies and the Indemnification
Agreement. Provided it can do so on commercially reasonable terms (as
determined in the sole discretion of the Board), the Company agrees during
your
tenure as Chief Executive Officer and, to the extent applicable to you,
thereafter to maintain at least the level of insurance coverage as is provided
for under the Policies as of the date of this letter
agreement.
4. Equity
Awards.
a. Initial
Stock Option Grant. Subject to your acceptance of this letter
and effective upon your Start Date, the Compensation Committee, under
authorization from the board, will grant you on the Start Date stock options (the
“Options”) to purchase 1,400,000
shares of the Company’s Common Stock with a per
share exercise price equal to the closing price of a share of the Company’s
common stock as reported on the Nasdaq Global Market on your Start
Date. The Option shares in each Option will vest and
become exercisable at the rate of 25% of the total number of Option shares
on
the first anniversary of your Start Date and l/48th of the total number of
Option shares on that same date of each month thereafter until you are
completely vested. Vesting will, of course, depend on your continued
and continuous service relationship with the Company. The Options may
at your election be incentive
stock options equal to the maximum number of shares permissible under the
Internal Revenue Code of 1986 and the applicable Treasury Regulations (currently
$100,000 of exercise price vesting in each calendar year) which will be granted
under the Company’s 2007 Equity Incentive Plan, and will be nonstatutory options
for the balance of the shares which will be granted under either or both of the
Company’s 2007 Equity Incentive
Plan and
Non-Qualified Stock Plan. Each Option will
have a ten-year term (subject to earlier termination in accordance with its
terms), and will be subject to the terms of the Stock Option Agreement between
you and the Company (which will incorporate the terms of Section 7.c.(ii) and
Section 7.c.(iii) below). Except in the event of a termination of
your employment for Cause, you will be able to exercise those Option shares
that
were vested on your last day of your service to the Company for, in the case
of
incentive stock options, three months following such last day, and in the case
of nonstatutory options, one year following such last day. In the
event of a termination for Cause for other than an act cited in Section
7.b.(i)(g), you will be able to exercise any vested Options within three months
following such Termination Date; however, if a termination for Cause
results from your Inability to Perform Services or your death, any vested
Options as of the Termination Date may be exercised within one year following
such Termination Date.
Mr. Ronald J. Prentki
July 2, 2008
Page 4
b. Subsequent
Equity Awards. Subject to the discretion of the Company’s
Board of Directors and the Committee, you may be eligible to receive additional
grants of stock options or other equity awards from time to time in the future,
on such terms and subject to such conditions as the Board shall determine as
of
the date of any such award.
5. Pre-employment
Conditions.
a. Confidentiality
Agreement. Your acceptance of this offer and commencement of
employment with the Company is contingent upon the execution, and delivery
to an
officer of the Company, of the Company’s Employee Confidential Information and
Inventions Agreement a copy of which is attached as Exhibit I for your
review and execution (the “Confidentiality Agreement”), prior to or on your
Start Date.
b. Right
to
Work. For purposes of federal immigration law, you will be
required to provide to the Company documentary evidence of your identity and
eligibility for employment in the United States. Such documentation
must be provided to us on your Start Date or our employment relationship will not become
effective.
6. No
Conflicting Obligations. You understand and agree that by
accepting this offer of employment, you represent to the Company that your
performance will not breach any other agreement to which you are a party and
that you have not, and will not during the term of your employment with the
Company, enter into any oral or written agreement in conflict with any of the
material provisions of this letter or the Company’s policies. You are
not to bring with you to the Company, or use or disclose to any person
associated with the Company, any confidential or proprietary information
belonging to any former employer or other person or entity with respect to
which
you owe an obligation of confidentiality under any agreement or
otherwise. The Company does not need and will not use such
information and we will assist you in any way possible to preserve and protect
the confidentiality of proprietary information belonging to third
parties. Also, we expect you to abide by any obligations to refrain
from soliciting any person employed by or otherwise associated with any former
employer and suggest that you refrain from having any contact with such persons
until such time as any non-solicitation obligation expires.
7. Termination
of
Employment.
a. At-Will
Employment. Subject only to the Company’s obligations
described in Sections 3.d., 7, 8, and 9, your employment with the Company will
be on an “at will” basis, meaning that either you or the Company may terminate
your employment at any time for any reason or no reason without further
obligation.
b. Termination
for Cause. If the Company terminates your employment at any
time for Cause, your salary shall cease on the date of termination, and you
will
not be entitled to any of the severance benefits detailed below other than
payment of items listed in clauses (i) through (iii) of the second paragraph
of
Section 7.c. and such other benefits as expressly required in such event by
applicable law or the terms of any applicable Company benefit plans
Mr. Ronald J. Prentki
July 2, 2008
Page 5
(i) Definition
of Cause. For purposes of this letter agreement, “Cause” shall
refer to any of the following that are materially injurious to the Company
and
shall mean your: (a) willful material or persistently repeated
failure to substantially perform your duties and responsibilities
hereunder, resulting in a timely written warning from the Board citing such
failure/s (other than a failure resulting from your complete or partial
incapacity due to physical or mental illness or impairment or disability);
(b)
willful act that constitutes gross misconduct; (c) willful breach of a material
provision of this letter (including the Confidentiality Agreement); (d) material
or willful violation of a federal or state law or regulation applicable to
the
business of the Company; (f)
your indictment for a felony;
or
(g) your commission of
a
fraud against the Company or any willful misconduct that brings the reputation
of the Company into material disrepute. No act or omission
by you
will be considered “willful”, unless it is determined that it was committed
without good faith or without a reasonable belief that the act or omission
was
in the best interests of the Company. Executive’s death or Inability
to Perform Services (as defined below) shall also constitute Cause for
termination. The
foregoing is an exclusive list of the acts or omissions that shall be considered
“Cause”. To effect a termination for Cause, preceded by a written
warning if effected under (a) above, the Board will provide you with a written
notice of its intent to effect such a termination and the reason therefor and
will give you 30 days from your receipt of such notice in which to cure any
act
or omission giving rise to Cause
(ii) Definition
of Inability to Perform Services. For purposes of this
Agreement, Cause to terminate your employment based on the your inability to
perform services shall exist if any illness or other incapacity renders the
you
physically or mentally unable to perform the essential functions of your
position, with or without reasonable accommodation, for a period in excess
of 12
workweeks in any consecutive 12 month period (“Inability to Perform
Services”). A physician selected in good faith by the Board shall
make a determination of whether you are physically or mentally unable to perform
the essential functions of your position, with or without reasonable
accommodation, subject to its review and consideration of all relevant
information..
c. Termination
Without Cause - Severance Benefits. In no way limiting the
Company’s policy of employment at-will, if your employment terminates in a
manner that constitutes an Involuntary Termination (as defined below in Section
7.(iv)), the Company will offer certain severance benefits to you. As
a condition to your receipt of such benefits, you are required to comply with
your continuing obligations to the Company (including the return of any Company
property), resign from all positions you hold with the Company including
membership on the Board (unless otherwise requested by the Board), and execute
the Company’s standard form of release agreement, as attached hereto as Exhibit II, releasing
any claims you may have against the Company, its agents and
successors.
Upon
termination of your employment for any reason (the last day of your employment
is referred to as your “Termination Date”), you will receive the following
payments as of the Termination Date: (i) all unpaid salary, if any, accrued through the
Termination Date; (ii) any bonuses earned prior to but unpaid as of the
Termination Date (including any such bonuses covered by Section 3.b.); and
(iii)
any unreimbursed business expenses and any unreimbursed relocation
expenses as specified in Section 9, both substantiated in accordance with
Company policy. The amounts under clauses (i) through (iii) in the
preceding sentence shall be paid to you without the condition of your providing
the Company with any release of claims.
Mr. Ronald J. Prentki
July 2, 2008
Page 6
(i) Payment
Upon Involuntary Termination. In the event that you experience
an Involuntary Termination, you will also be entitled to receive (i) cash
severance equal to an amount equal to 24 months of your then-current Base Salary
and (ii) continuance of payment by the Company of its portion of the health
insurance benefits provided to you immediately prior to your Involuntary
Termination pursuant to the terms of the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”) or other applicable law for a
maximum of either 12 months following your Termination Date or until you become
eligible for health insurance coverage from another source, whichever occurs
sooner (provided that you must promptly inform the Company, in writing, if
you
become eligible for health insurance coverage from another source within 12
months after the termination).. Subject to any delay required under
Section 9 below, the cash severance amount set forth in this Section 7.c.(i)
shall be paid within 30 days after an Involuntary Termination, subject to the
Company’s receipt of your effective release of claims referred to
above.
(ii) Vesting
Acceleration on Involuntary Termination occurring absent a Change of
Control. In addition to the benefits provided in Section
7.c.(i) above, but only with respect to an Involuntary Termination not covered
by Section 7.c.(iii) below, you will be entitled to additional vesting of equity
incentives effective as of your Termination Date such that as of the effective
date of your Involuntary Termination you will be treated as vested in a number
of equity incentive shares equal to the total number of equity incentive shares
that would have vested
in
accordance with their
terms in the 12 month
period following the date of your
Involuntary Termination
in addition to
the number of equity incentive shares in which you would
otherwise be vested in on the date of your Involuntary Termination.
(iii) Change
of
Control Acceleration. In the event: (i) you
experience an Involuntary Termination in connection with a Change of Control
(the Involuntary Termination shall be deemed to be in connection with a Change
of Control if the Involuntary Termination occurs within 30 days prior to the
Change of Control or is required by the merger agreement or other instrument
relating to such Change of Control or is made at the express request of the
other party to the transaction constituting such Change of Control or within
one
year following a Change of Control of the Company), you will 100% vest in all
of
the shares subject to your outstanding and unvested equity incentives upon
the
effective date of your Involuntary Termination; or (ii) if any of your equity
incentives are terminating in a Change of Control because the successor entity
has not agreed to assume or substitute for such equity incentives in connection
with the transaction, you will immediately vest in all such equity incentives
for 100% of the shares subject to such equity incentives effective on the date
on which any such equity incentive is terminating in connection with the
transaction, as applicable.
Mr. Ronald J. Prentki
July 2, 2008
Page 7
As
used
herein, a “Change of Control” means the occurrence of any of the following
events:
(a) the
consummation of a merger or consolidation of the Company with any other
corporation, other than a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto
continuing to represent (either by remaining outstanding or by being converted
into voting securities of the surviving entity or its parent) at least
50% of the total voting power represented by the voting securities of the
Company or such surviving entity or its parent outstanding immediately after
such merger or consolidation;
(b) the
consummation of the sale or disposition of all or substantially all of the
Company’s assets to any other person or entity (other than to a wholly-owned
subsidiary); or
(c) any
“person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act)
becomes the “beneficial owner”(as defined in Rule 13d-3 of the Exchange Act),
directly or indirectly, of securities representing 50% or more of the total
voting power represented by the Company’s then outstanding voting
securities
(iv) Definition
of Involuntary Termination. For purposes of this letter
agreement, an Involuntary Termination is any termination of your employment
with
the Company or its acquirer or successor, as the case may be, which is
either: (i) by the Company (or its acquirer or successor) without
Cause; (ii) by you for Good Reason; or (iii) the liquidation or
dissolution of the Company or its ceasing operations other than temporary
cessation resulting from Acts of God.
(v) Definition
of Good Reason. For purposes of this letter agreement, you
will have “Good Reason” to terminate your employment upon the occurrence of any
of the following without your express written consent: (i) a change
in your responsibilities, titles or offices (including your position as a member
of the Board), or any removal of you from, or any failure to re-elect you to,
any of such positions, or causing you or requiring you to report to anyone
other
than the Board, which has the effect of materially diminishing your
responsibility or authority, including without limitation that you are no longer
the sole chief executive officer of the Company; (ii) a reduction of
your Base Salary or Target Bonus; (iii) a material reduction in the
level or kind of employee benefits to which you were entitled immediately prior
to such reduction with the result that your overall benefits package is
significantly reduced; (iv) a substantial reduction, without good
business reasons, of the facilities and perquisites (including office space
and
location) available to you immediately prior to such reduction; (v)
relocation of your primary place of business for the performance of your duties
to the Company to a location that is more than 50 miles from the location
specified in Section l.a.; (vi) any material breach of a material
provision of this letter agreement by the Company (including without limitation
the failure to timely provide you the cash compensation, equity compensation
and/or employee benefits owed you under this letter agreement);
or (vii) any failure or refusal of a successor company to the
Company’s business to expressly agree in writing to assume the Company’s
obligations hereunder.
Mr. Ronald J. Prentki
July 2, 2008
Page 8
(vi) No
Obligation of You to Mitigate. No payment or benefit made to
you or to be made to you pursuant to this letter agreement shall be subject
to
offset, as the amount of any payment provided for in this
Section 7 shall not be reduced, offset or subject to recovery by the
Company by reason of any compensation earned by you as the result of employment
by another employer after your Termination Date, or by reason of your failure
to
seek other employment, or otherwise, except for the possible early termination
of health insurance benefits as provided in Section 7.c.(i).
8. Section
409A Tax
Matters. In the event that the Company determines that any of your
severance benefits payments fails to satisfy the distribution requirement of
Section 409A(a)(2)(A) of the Internal Revenue Code (the “Code”) as a result of
Section 409A(a)(2)(B)(i) of the Code, the payment of such benefit shall be
accelerated to the minimum extent necessary so that the benefit is not subject
to the provisions of Section 409A(a)(1) of the Code; for these purposes,
each severance payment is hereby designated as a separate payment and will
not
collectively be treated as a single payment. (The payment schedule as revised
after the application of the preceding sentence shall be referred to as the
“Revised Payment Schedule.”) However, in the event the payment of benefits
pursuant to the Revised Payment Schedule would be subject to Section 409A(a)(1)
of the Code, the payment of such benefits shall not be paid pursuant to the
Revised Payment Schedule and instead the payment of such benefits shall be
delayed to the minimum extent necessary so that such benefits are not subject
to
the provisions of Section 409A(a)(1) of the Code. The Board shall attach
conditions to and/or adjust the amounts paid pursuant to this Section 8 to
preserve, as closely as possible, the economic consequences that would have
applied in the absence of this Section 8; provided, however, that no such condition
and/or adjustment shall result in the payments being subject to Section
409A(a)(1) of the Code.
9. Relocation
Reimbursement. In addition
to
other benefits provided to you herein by the Company, the Company will reimburse
you for the following costs and expenses:
a. up
to
$150,000 to cover expenses incurred by you in the sale of your home
(documented); covered expenses include realtor commissions, transfer
taxes, legal fees, title insurance charges, escrow fees and other similar
expenses directly related to the sale of your home;
b. costs
of
moving usual household and personal goods;
c. costs
of
moving automobiles (if sold instead of moved, comparable credit extended towards
costs of additional house-hunting relocation trips);
d. up
to
three months of temporary housing;
e. up
to
three months storage of moved goods;
f. costs
of
a total of four house-hunting/relocation trips for you or your spouse;
and
g. costs
of
final move for you and your spouse.
Mr. Ronald J. Prentki
July 2, 2008
Page 9
10. Miscellaneous.
a. Notice. Notices
and all other communications contemplated by this letter agreement shall be
in
writing and shall be deemed to have been duly given when personally delivered
or
when mailed by overnight courier, U.S. registered or certified mail, return
receipt requested and postage prepaid. In the case of yourself,
mailed notices shall be addressed to you at the home address that you most
recently communicated to the Company in writing. In the case of the
Company, mailed notices shall be addressed to its corporate headquarters, and
all notices shall be directed to the attention of its Chairman of the
Board.
b. Priority. Terms
and definitions specified in this letter agreement shall supersede those
contained within other supportive agreements, such as stock option plans and
their standard agreements.
c. Assignment. This
letter agreement shall not be assignable by either party and shall be binding
upon, and shall inure to the benefit of, the heirs, executors, administrators,
legal representatives, successors and assigns of the parties. In the
event that all or substantially all of the business, assets and/or stock of
the
Company is sold or transferred, then this letter agreement shall be binding
on
the transferee of the business, assets and/or stock.
We
are
all delighted to be able to extend you this offer and look forward to working
with you. To indicate your acceptance of the Company’s offer, please
sign and date this letter in the space provided below and return it to me on
or
before July 3, 2008,
along with a signed and
dated original copy of the Employee Confidential Information and Inventions
Agreement. This letter, together with the Employee Confidential
Information and Inventions Agreement and the agreements expressly referenced
herein, set forth the terms of your employment with the Company and supersede
any prior representations or agreements, whether written or
oral. This letter will be governed by the laws of California, without
regard to its conflict of laws provisions. In the event of any
conflict in terms between this letter agreement and any other agreement between
you and the Company (including without limitation the two Attachments and the
other agreements referenced herein), the terms of this letter agreement shall
prevail. This letter agreement may not be modified or amended, except
by a written agreement, signed by the Chairman of the Board and
yourself. No waiver by either party of any breach of, or of
compliance with, any condition or provision of this letter agreement by the
other party shall be considered a waiver of any other condition or provision
or
of the same condition or provision at another time.
Mr. Ronald J. Prentki
July 2, 2008
Page 10
Very
truly yours,
A.P.
PHARMA, INC.
By:
/s/
Paul
Goddard
Paul
Goddard, Chairman of the
Board
ACCEPTED
AND AGREED:
Ronald
J. Prentki
/s/
Ronald J.
Prentki Date July
3,
2008
Signature
Exhibit
I:
Employee Confidential Information and Inventions Agreement
Exhibit
II: Form
of Release of Claims